Royal Bank of Canada’s Alaunos Therapeutics TCRT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1K | Buy |
+185
| New | +$553 | ﹤0.01% | 6959 |
|
|
2025
Q4 | – | Sell |
-198
| Closed | – | – | 7629 |
|
|
2025
Q3 | $0 | Buy |
+198
| New | +$564 | ﹤0.01% | 7522 |
|
|
2025
Q2 | – | Sell |
-100
| Closed | – | – | 7339 |
|
|
2025
Q1 | $0 | Sell |
100
-8
| -7% | -$13 | ﹤0.01% | 7218 |
|
|
2024
Q4 | $0 | Buy |
+108
| New | +$240 | ﹤0.01% | 7241 |
|
|
2024
Q3 | – | Sell |
-35
| Closed | – | – | 7423 |
|
|
2024
Q2 | $0 | Buy |
35
+30
| +600% | +$358 | ﹤0.01% | 7521 |
|
|
2024
Q1 | $0 | Sell |
5
-5
| -50% | -$100 | ﹤0.01% | 7577 |
|
|
2023
Q4 | $0 | Sell |
10
-494
| -98% | -$5.95K | ﹤0.01% | 7571 |
|
|
2023
Q3 | $10K | Buy |
504
+496
| +6,200% | +$21.4K | ﹤0.01% | 6424 |
|
|
2023
Q2 | $1K | Buy |
8
+3
| +60% | +$243 | ﹤0.01% | 7085 |
|
|
2023
Q1 | $0 | Buy |
5
+3
| +150% | +$286 | ﹤0.01% | 7466 |
|
|
2022
Q4 | $0 | Sell |
2
-118
| -98% | -$17.1K | ﹤0.01% | 7706 |
|
|
2022
Q3 | $31K | Buy |
120
+63
| +111% | +$18.3K | ﹤0.01% | 5967 |
|
|
2022
Q2 | $10K | Sell |
57
-84
| -60% | -$8.03K | ﹤0.01% | 6393 |
|
|
2022
Q1 | $13K | Sell |
141
-199
| -59% | -$25.5K | ﹤0.01% | 6842 |
|
|
2021
Q4 | $56K | Buy |
340
+164
| +93% | +$36K | ﹤0.01% | 6312 |
|
|
2021
Q3 | $48K | Buy |
176
+26
| +17% | +$7.95K | ﹤0.01% | 6193 |
|
|
2021
Q2 | $60K | Buy |
150
+3
| +2% | +$1.4K | ﹤0.01% | 5913 |
|
|
2021
Q1 | $80K | Buy |
147
+47
| +47% | +$29.3K | ﹤0.01% | 5606 |
|
|
2020
Q4 | $38K | Sell |
100
-5
| -5% | -$1.99K | ﹤0.01% | 5773 |
|
|
2020
Q3 | $40K | Sell |
105
-2
| -2% | -$884 | ﹤0.01% | 5439 |
|
|
2020
Q2 | $53K | Buy |
107
+14
| +15% | +$6.24K | ﹤0.01% | 5204 |
|
|
2020
Q1 | $34K | Buy |
93
+43
| +86% | +$22.3K | ﹤0.01% | 5327 |
|
|
2019
Q4 | $36K | Sell |
50
-90
| -64% | -$61.9K | ﹤0.01% | 5604 |
|
|
2019
Q3 | $90K | Sell |
140
-68
| -33% | -$53.9K | ﹤0.01% | 4852 |
|
|
2019
Q2 | $182K | Buy |
208
+56
| +37% | +$38.5K | ﹤0.01% | 4535 |
|
|
2019
Q1 | $88K | Buy |
152
+33
| +28% | +$13.8K | ﹤0.01% | 4853 |
|
|
2018
Q4 | $33K | Sell |
119
-115
| -49% | -$45.5K | ﹤0.01% | 5327 |
|
|
2018
Q3 | $113K | Buy |
234
+51
| +28% | +$21.9K | ﹤0.01% | 4796 |
|
|
2018
Q2 | $83K | Buy |
183
+10
| +6% | +$6.34K | ﹤0.01% | 4905 |
|
|
2018
Q1 | $101K | Buy |
173
+5
| +3% | +$3.12K | ﹤0.01% | 4693 |
|
|
2017
Q4 | $105K | Sell |
168
-64
| -28% | -$46K | ﹤0.01% | 4788 |
|
|
2017
Q3 | $214K | Buy |
232
+75
| +48% | +$66.6K | ﹤0.01% | 4471 |
|
|
2017
Q2 | $147K | Sell |
157
-21
| -12% | -$20.6K | ﹤0.01% | 4551 |
|
|
2017
Q1 | $170K | Sell |
178
-78
| -30% | -$72.6K | ﹤0.01% | 4449 |
|
|
2016
Q4 | $206K | Buy |
256
+88
| +52% | +$79.3K | ﹤0.01% | 4471 |
|
|
2016
Q3 | $143K | Buy |
168
+40
| +31% | +$32.2K | ﹤0.01% | 4635 |
|
|
2016
Q2 | $105K | Buy |
128
+20
| +19% | +$21.8K | ﹤0.01% | 4763 |
|
|
2016
Q1 | $120K | Hold |
108
| – | – | ﹤0.01% | 4668 |
|
|
2015
Q4 | $134K | Buy |
108
+2
| +2% | +$3.31K | ﹤0.01% | 4782 |
|
|
2015
Q3 | $143K | Buy |
106
+91
| +607% | +$150K | ﹤0.01% | 4546 |
|
|
2015
Q2 | $27K | Sell |
15
-28
| -65% | -$43.5K | ﹤0.01% | 5551 |
|
|
2015
Q1 | $70K | Buy |
43
+13
| +43% | +$19.3K | ﹤0.01% | 4806 |
|
|
2014
Q4 | $23K | Buy |
30
+17
| +131% | +$9.03K | ﹤0.01% | 5364 |
|
|
2014
Q3 | $5K | Sell |
13
-17
| -57% | -$8.2K | ﹤0.01% | 5648 |
|
|
2014
Q2 | $18K | Sell |
30
-138
| -82% | -$76.8K | ﹤0.01% | 5236 |
|
|
2014
Q1 | $115K | Buy |
168
+11
| +7% | +$7.37K | ﹤0.01% | 4478 |
|
|
2013
Q4 | $102K | Sell |
157
-13
| -8% | -$7.74K | ﹤0.01% | 4563 |
|
|
2013
Q3 | $101K | Buy |
170
+3
| +2% | +$1.35K | ﹤0.01% | 4471 |
|
|
2013
Q2 | $53K | Buy |
+167
| New | +$46.4K | ﹤0.01% | 4638 |
|
Other funds holding TCRT
VFT
VCM
HF
XT
Royal Bank of Canada's TCRT Position: Q1 2026 in Review
Royal Bank of Canada opened a new position in Alaunos Therapeutics (TCRT) in Q1 2026: 185 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #6959 among its holdings. This is a return to the name: Royal Bank of Canada previously reported a position in TCRT as recently as Q3 2025.
Royal Bank of Canada first reported a position in TCRT in Q2 2013 and has held it in 49 quarters since. The position peaked at $214K in Q3 2017. 29 funds tracked by Wall St. Rank hold TCRT as of Q1 2026.
- Royal Bank of Canada held 185 shares of Alaunos Therapeutics worth $1K as of Q1 2026.
- Alaunos Therapeutics was a new Royal Bank of Canada position in Q1 2026.
- Alaunos Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6959 holding.
- Royal Bank of Canada first reported a position in Alaunos Therapeutics in Q2 2013 and has held it in 49 quarters since.
- Royal Bank of Canada's Alaunos Therapeutics position peaked at $214K in Q3 2017.
- 29 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.